Tenax Therapeutics is trading at $2.08 (+5.05%) in pre-market; investor interest may be supported by its scheduled presentation, though no verified September 9, 2026 company announcement directly explains the increase.
- The presentation is scheduled for 8:35 a.m. EDT on September 9, 2026.
- Recent coverage highlighted a potential 26.3-meter benefit for a prespecified subgroup after the Phase 3 LEVEL trial missed its primary endpoint, but its connection to the move is unconfirmed.